Business
Egle Therapeutics Appoints John Celebi as Chief Executive Officer
PARIS, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company pioneering precision medicines that modulate regulatory T cells (Tregs) to rebalance immune function in patients with autoimmune diseases and cancer, today announced the appointment of John Celebi, M.B.A., as chief executive officer. Mr. Celebi is a seasoned biotechnology executive with over 30 years of experience building and scaling innovative life sciences companies and has been a mem
About this update from Sensei Biotherapeutics, Inc.
[{"type":"image","alt":"Egle Therapeutics","displaySize":"","headline":null,"caption":"Egle Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":195,"url":"https://media.zenfs.com/en/globenewswire.com/3db9bf8debfdfd2597640451b013694a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/t0qWWVuK7NybEue175fe7A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI3MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3db9bf8debfdfd2597640451b013694a","width":300,"height":195}},"lazy":false},{"type":"text","content":"PARIS, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company pioneering precision medicines that modulate regulatory T cells (Tregs) to rebalance immune function in patients with autoimmune diseases and cancer, today announced the appointment of John Celebi, M.B.A., as chief executive officer. Mr. Celebi is a seasoned biotechnology executive with over 30 years of experience building and scaling innovative life sciences companies and has been a member of the Egle board of directors since 2024.","length":546,"tagName":"p"},{"type":"text","content":"Mr. Celebi's appointment comes as Egle enhances its clinical development focus on autoimmune diseases, where recent validation of the IL-2 mechanism has created a significant opportunity for differentiated therapies in major indications. The company's lead programs are novel IL-2 receptor alpha-biased muteins designed with best-in-class selectivity for regulatory T cells, offering the potential for deeper efficacy, improved safety, and sustained immune rebalancing without Treg exhaustion.","length":501,"tagName":"p"},{"type":"text","content":"“As Egle deepens its focus on autoimmune diseases, the appointment of John represents a strategic and thoughtful evolution of our leadership team,” said Michel Detheux, Ph.D., Chair of the Board of Egle Therapeutics. “John is an accomplished leader whose service on Egle’s board brings valuable continuity to our vision and disciplined execution. His proven track record in building biotechnology companies from early stages through successful public market offerings, combined with his expertise in strategic partnerships and therapeutics development, positions Egle to capitalize on the significant opportunity in Treg biology. We are confident his leadership will accelerate our mis...